We are now committed to developing a single broad-spectrum nanoviricide drug that attacks all four serotypes of dengue and their variants. We are also making progress in the development of a single broad-spectrum nanoviricide for many different viral infections of the external eye, including EKC and herpes keratitis, he said further, explaining the additional license agreement that, the Market Sizes for these diseases are anticipated to be in the billions of dollars. We were negotiating a license agreement for these viruses with TheraCour for some time now, and we have been able to execute it on terms that are extremely favorable for our shareholders.

We continue to be frugal and productive in our operations. The strong shareholder equity and cash holdings should enable us to move onto a National Stock Exchange, said Eugene Seymour, MD, MPH, CEO of the Company, adding, We have been preparing to apply for a listing on either NASDAQ or the American Stock Exchange (Amex).

Source: NanoViricides, Inc.